Tagged With Bristol-myers Squibb

Warren Buffett's Berkshire Hathaway plowed more than $5 billion into 4 pharma stocks last quarter. He's been teasing a bet on the sector for more than 20 years


AbbVie, Merck, and Pfizer shares jump after Warren Buffett's Berkshire Hathaway reveals it bought them last quarter


MyoKardia soars 59% after Bristol-Myers agrees to acquire it for $13 billion in cash



Rep. Katie Porter ripped into pharma executive Mark Alles for repeated price hikes on the cancer drug Revlimid


US stocks climb as better-than-expected jobless claims offset stimulus concerns


US stocks edge lower as investors weigh better-than-expected jobless claims against stimulus worries



Amgen will buy a blockbuster psoriasis drug for $13.4 billion — and it's part of a plan to get Celgene's mega-merger with Bristol-Myers Squibb approved


Bristol-Myers Squibb is selling off a blockbuster drug to help its $74 billion merger with Celgene get approved — and now both stocks are tumbling


Dispensed: Pharma CEOs on Capitol Hill, the exploding CBD market, and treating kids with new models of primary care


Opposition to Bristol-Myers Squibb's $74 billion acquisition of Celgene could endanger the deal, and the whole situation is 'somewhat unprecedented'


Bristol-Myers' record-breaking $74 billion biotech deal is in jeopardy


The biggest healthcare investor conference starts on Monday — here are the top 5 areas we're keeping an eye on



Dispensed: A $74 billion mega-merger starts 2019 off with a bang and how a health system plans to disrupt itself before it's disrupted


Bristol-Myers Squibb is buying Celgene in a $74 billion deal


'We are going to have lung cancer patients living longer and better': A new kind of cancer treatment is about to change how we treat the disease


2 cancer drugmakers just presented key data about how new treatments work in lung cancer -- and the markets picked a winner



We're about to get some key lung cancer data -- and it could affect how hundreds of thousands of cancer patients are treated


Pharma giant Bristol-Myers Squibb just made another big bet on cancer immunotherapy


A small drug company that's trying to make cancer treatments safer just received a huge endorsement


Carl Icahn just jumped into a $90 billion drug maker, and people are betting it will be a takeover target